NCT05809986 - Ofatumumab in Portuguese Multiple Sclerosis Patients - an Observational Study | Biotech Hunter

Enrollment

174

Participants

Timeline

Start Date

November 27, 2023

Primary Completion Date

September 15, 2026

Study Completion Date

September 15, 2026

Conditions

Relapsing Multiple Sclerosis

Interventions

OTHER

Ofatumumab

There is no treatment allocation. Ofatumumab will be prescribed by the physician as per locally approved label. No drug will be dispensed from Novartis

Trial Locations (10)

2720-276

RECRUITING

Novartis Investigative Site, Amadora

4835-044

RECRUITING

Novartis Investigative Site, Guimarães

2410-104

RECRUITING

Novartis Investigative Site, Leiria

1169 050

RECRUITING

Novartis Investigative Site, Lisbon

1349-019

RECRUITING

Novartis Investigative Site, Lisbon

1649 035

RECRUITING

Novartis Investigative Site, Lisbon

4454 513

RECRUITING

Novartis Investigative Site, Matosinhos Municipality

4990 041

RECRUITING

Novartis Investigative Site, Ponte de Lima

4200 319

RECRUITING

Novartis Investigative Site, Porto

2910-446

RECRUITING

Novartis Investigative Site, Setúbal